Skip to content
DataLookout
Menu

NCT07920731

A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer

StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: From first antitumor treatment until disease progression or death from any cause, whichever occurs first; assessed throughout treatment and survival follow-up, up to 24 months after the last patient is enrolled

Arms and interventions

imotuzumab combined with the NALIRIFOX chemotherapyOther

Drugs: imotuzumab combined with the NALIRIFOX chemotherapy

Sites

1 site in 1 country

  • FUSCCShanghai, Shanghai Municipality, China